№ files_lp_4_process_2_47037
File format: docx
Character count: 9056
File size: 102 KB
A collection of experimental protocols, figures, and results describing the isolation and characterization of regulatory T cells, their genetic manipulation, immune function analyses, and small-molecule screening targeting Nr4a transcription factors.
Year:
2023
Institution:
Keio University School of Medicine
Type of document:
Research supplementary methods and figure legends
Field:
Immunology / Molecular biology
Methods:
Human PBMC isolation, Treg cell sorting, plasmid construction, ELISA, luciferase-based drug screening, flow cytometry, qPCR
Ethics approval:
Keio University Institutional Review Board (Approval number: 20120039)
Species studied:
Human, Mouse
Target molecules:
Nr4a1, Nr4a2, Foxp3, IFN-γ
Experimental models:
WT and Nr4a-DcKO mice, 293T cells
Compounds tested:
SCADS inhibitor kit, camptothecin, SN-38
Data type:
Flow cytometry profiles, ELISA measurements, quantitative PCR, luciferase assay results
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year of completion:
2023
Field:
Cancer research and tumor immunology
Research focus:
PPP2R2A deletion and expression in NSCLC and immunotherapy response
Type of document:
Supplementary materials and methods section of a scientific study
Data sources:
cBioPortal Pan-Lung cancer dataset; TCGA pan-cancer RNA-Seq data via Xena Browser; Kmplot survival database
Cell lines:
A549 cells; CMT167 PPP2R2A heterozygous knockout cells
Animal models:
CD11b-DTR mice (Jackson Laboratory, strain 006000); C57BL6 mice
Experimental techniques:
RNA sequencing; Gene Set Enrichment Analysis (GSEA); glycosylation assays with PNGase F and Endo H; adoptive Treg transfer; flow cytometry; Treg suppression assay with CellTrace Violet; ELISA
Repositories:
NCBI GEO (accession number GSE311238)
Analytes:
PD-L1, TNF-α, IFN-γ, IFN-α, IFN-β
Antibodies and reagents:
Anti-Mouse PD-L1 In Vivo Antibody (Clone 10F.9G2, Ichorbio); reagents from BioLegend, STEMCELL Technologies, eBioscience, R&D Systems, PBL Assay Science
Cited works:
Gyorffy B., 2024, Innovation (Camb); Qiu Z. et al., 2020, Cancer Research; Zhou L. et al., 2024, Journal of Clinical Investigation
Year:
2019
Region / City:
England
Topic:
Heart Failure, Treatment, Cardiovascular Disease
Document Type:
Guidance
Organization:
National Institute for Health and Care Excellence (NICE)
Author:
National Institute for Health and Care Excellence
Target Audience:
General practitioners, healthcare providers
Period of validity:
Ongoing
Approval Date:
August 2019
Date of Changes:
N/A
Year:
2018
Region / city:
London
Theme:
Dementia care, pharmacology
Document type:
Clinical guideline
Organization / institution:
London Dementia Clinical Network (NHS England and Improvement London Region)
Author:
Delia Bishara (Consultant Pharmacist, South London and Maudsley NHS Foundation Trust)
Target audience:
Healthcare professionals involved in dementia care
Effective period:
2018–present
Approval date:
Not specified
Date of amendments:
Not specified
Journal:
World Journal of Gastroenterology
Manuscript NO:
90838
Manuscript Type:
Letter to the Editor
Authors:
Francesca Colapietro, Nicola Pugliese, Antonio Voza, Alessio Aghemo, Stella De Nicola
Affiliations:
Department of Biomedical Sciences, Humanitas University, Milan, Italy; Division of Internal Medicine and Hepatology, Department of Gastroenterology, Humanitas Research Hospital, Milan, Italy; Department of Emergency, Humanitas Research Hospital, Milan, Italy
Corresponding Author:
Francesca Colapietro, MD, Department of Biomedical Sciences, Humanitas University, Milan, Italy, [email protected]
Received:
December 15, 2023
Revised:
January 11, 2024
Accepted:
February 18, 2024
Keywords:
Chronic hepatitis B, Reactivation, Nucleoside analogue, Tyrosine kinase inhibitors, Onco-hematology
Study Type:
Case report and literature review
Patient Details:
67-year-old Caucasian male with chronic lymphocytic leukemia, HBsAg-/anti-HBc+
Treatment:
Tyrosine kinase inhibitors, specifically acalabrutinib
Clinical Outcome:
HBV reactivation with liver failure, treated with nucleos(t)ide analogues
Year:
2026
Region / City:
N/A
Topic:
Cancer research, Immunotherapy
Document Type:
Research article
Organization / Institution:
N/A
Author:
Walid S. Kamoun, Anne-Sophie Dugast, James J. Suchy, Stephanie Grabow, Ross B. Fulton, James F. Sampson, Lia Luus, Michael Santiago, Alexander Koshkaryev, Gang Sun, Vasileios Askoxylakis, Eric Tam, Zhaohua Richard Huang, Daryl C. Drummond, Andrew J. Sawyer
Target Audience:
Researchers, Oncology professionals
Period of Action:
N/A
Approval Date:
N/A
Modification Date:
N/A
Year:
2026
Region / city:
Missouri
Document Type:
Proposal
Organization:
MO HealthNet
Author:
MO HealthNet, Conduent
Target Audience:
MO HealthNet participants, healthcare providers
Period of validity:
Ongoing
Approval Date:
January 20, 2026
Revision Date:
May 21, 2008
Criteria Status:
Revision of Existing Criteria
Year:
2023
Region / city:
Not specified
Topic:
Ophthalmology, Medical Drugs
Document Type:
Medical Authorization Form
Organization / Institution:
Not specified
Author:
Not specified
Target audience:
Healthcare Providers
Effective period:
Not specified
Approval date:
Not specified
Amendment date:
Not specified
Context:
Medical request form for prior authorization of ophthalmic VEGF inhibitors, detailing drug choices and criteria for approval.
Year:
2022
Region / city:
Viseu Dão-Lafões
Topic:
Spondyloarthritis, TNF-alpha inhibitors, Biosimilars, Treatment Efficacy, Safety
Document type:
Research Study
Institution:
Unidade Local de Saúde Viseu Dão-Lafões
Author:
Inês Almeida, Liliana Saraiva, Miguel Tavares, Ana Teixeira, Maura Couto
Target audience:
Healthcare professionals, researchers, rheumatologists
Period of validity:
January 2010 - May 2022
Approval date:
Not specified
Date of changes:
Not specified
Year:
2025
Region / city:
Not specified
Topic:
Achondroplasia, FGFR3, Tyrosine Kinase Inhibitors, Genetic Disorders
Document Type:
Research Letter
Organization:
Not specified
Author(s):
Not specified
Target Audience:
Medical professionals, researchers
Period of validity:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Contextual description:
A research letter summarizing recent advancements in the treatment and genetic understanding of achondroplasia, particularly focusing on selective FGFR3 tyrosine kinase inhibitors.
Year:
2015
Region / City:
Southeastern/Southwest United States
Field:
Medicine, Oncology
Document Type:
Abstract
Organization:
Texas Tech University Health Sciences Center, University of Pennsylvania
Author:
Paul Trippier, Kshitij Verma, Tianzhu Zang, Trevor M. Penning
Target Audience:
Researchers, Medical Professionals
Effective Period:
Not specified
Approval Date:
Not specified
Date of Last Update:
Not specified
Year:
2015
Region / City:
Nice, France
Field:
Hepatology, Virology, Infectious Diseases
Document Type:
Original Article, Observational Study
Institution:
Archet Hospital, Centre Hospitalier Universitaire
Author(s):
Alissa Naqvi, Valérie Giordanengo, Brigitte Dunais, Francine de Salvador-Guillouet, Isabelle Perbost, Jacques Durant, Pascal Pugliese, Aline Joulié, Pierre Marie Roger, Eric Rosenthal
Target Audience:
Medical Researchers, Healthcare Professionals, Clinicians
Period of Study:
August 2011 - October 2013
Approval Date:
2015
Date of Last Revision:
March 17, 2015
Date Published:
July 21, 2015
Subject:
Biology
Topic:
Enzyme activity and enzyme kinetics
Focus enzyme:
Trypsin
Substrate:
Casein (milk protein)
Independent variables:
Temperature; pH; Substrate concentration; Inhibitor type (green tea, black tea)
Dependent variable:
Time taken for suspension to clear; Rate of reaction (1/t)
Control treatments:
Milk without trypsin; Trypsin with water (no inhibitor)
Materials:
3% milk suspension; 1% trypsin solution; buffer solutions (pH 2, 4, 7, 10); green tea; black tea; water baths; ice bath; colorimeter (alternative method)
Experimental methods:
Measurement of clearing time in milk suspension; Optional colorimetric measurement of light transmission
Educational level:
Laboratory session for learners
Session number:
5
Reference cited:
Qie, X. et al. (2021), Food Research International, vol. 140
Year:
2026
Cell lines:
MV4-11, K562
Type:
Supplementary figures for research article
Techniques:
RNA-Seq, KEGG pathway analysis, PCR, capillary electrophoresis, lentiviral transduction
Genes analyzed:
FLT3, GAMT, SLC7A1, SLC6A9
Treatments:
DMSO, FLT3 inhibitors (AC220, crenolanib, gilteritinib)
Data sources:
TCGA LAML dataset, GTEx database
Significance threshold:
P < 0.05
Replication:
3 biological replicates for RNA-Seq
Endogenous and transduced gene variants:
wild type FLT3, FLT3-ITD N51
Experimental period:
24 hours
Supplement type:
Figures for supplementary material
RNA expression format:
log2 (TMP+1)
Year:
2020–2024
Study type:
Randomized controlled trial
Drug class:
SGLT2 inhibitors (Empagliflozin, Dapagliflozin, Sotagliflozin)
Patient population:
Adults with acute heart failure or worsening heart failure, including those with type 2 diabetes
Sample size:
33–1,222 patients per study
Primary outcomes:
Clinical endpoints, urine output, diuretic response, NT-proBNP changes, weight change, cardiovascular events
Secondary outcomes:
Hemoconcentration, plasma osmolality, urinary sodium and glucose excretion, KCCQ-TSS, hospitalization rates
Treatment duration:
3 days–4 weeks
Geographic context:
Multicenter international studies
Eligibility criteria:
Age ≥18 years, signs of congestion, eGFR ≥15–30 mL/min/1.73 m² depending on study, stabilized hemodynamics
Safety outcomes:
Renal function, electrolyte changes, body weight, adverse events
Year:
2019–2024
Region:
International
Topic:
Oncology / Hepatocellular Carcinoma
Document Type:
Meta-analysis
Institution:
Multiple clinical research centers
Authors:
Various (from included RCTs)
Target Audience:
Medical researchers, oncologists, clinicians
Study Design:
Randomized controlled trials, Phase II and III
Interventions:
Nivolumab, Pembrolizumab, Atezolizumab, Sintilimab
Comparators:
Placebo, standard care, active surveillance
Outcomes Measured:
Overall survival (OS), Recurrence-free survival (RFS), adverse events (AEs)
Sample Size:
Data pooled from 10 studies
Statistical Methods:
DerSimonian-Laird random-effects model, hazard ratios (HRs), risk ratios (RRs)
Adverse Events Reported:
Fatigue, hypertension, elevated liver enzymes (grade 3+)
Publication Type:
Peer-reviewed articles
Description:
Systematic review and meta-analysis of clinical trials assessing survival outcomes and safety of adjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma after curative treatment.
Year:
2026
Region / City:
Ile Oluji, Ondo State, Nigeria
Subject:
Corrosion inhibition, quantum chemical analysis
Document Type:
Research article
Institution:
Not specified
Author:
Not specified
Target Audience:
Researchers in computational chemistry and corrosion science
Methodology:
Hartree-Fock Density Functional Theory (HF-DFT), Gas Chromatography-Mass Spectrometry (GC-MS), High-Performance Liquid Chromatography (HPLC)
Key Compounds:
Cola acuminata extract components
Parameters Analyzed:
EHOMO, ELUMO, energy gap (ΔE), dipole moment (μ), absolute hardness (η), softness (S), electron affinity (A), ionization energy (I)
Purpose:
Investigation of agreement between quantum chemical predictions and experimental inhibition efficiencies